Stockhouse

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides ...

REC-3964 is Recursion’s first new chemical entity developed using the RecursionOS. REC-3964 represents a novel, non-antibiotic approach with a unique mechanism of action that binds and ...

Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?

Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Stockhouse

Recursion Releases MolRec, a Compound Intelligence Tool for Drug Discovery, Alongside the Largest of Its Kind Open-Source Dataset During First R&D Day

For the first time ever, a demonstration version of one of Recursion's Compound Intelligence tools to explore maps of biology and chemistry is open for anyone to use RxRx3, the underlying dataset ...